Treatment for Acute Agitation in Patients with Dementia

Assessment and Initial Management

The American Psychiatric Association recommends thoroughly assessing the type, frequency, severity, pattern, and timing of agitation symptoms to guide appropriate intervention 1, 2
Evaluation for potentially modifiable contributors to agitation, particularly pain, is crucial as it is often undertreated and can manifest as agitation in dementia patients 3, 4
Quantitative measures should be used to assess the severity of agitation and response to treatment 2

The American Psychiatric Association suggests implementing person-centered nonpharmacological interventions before considering medication 5
Developing individualized care plans addressing environmental factors, sensory needs, and personal preferences is recommended 6
Environmental modifications, such as reducing noise and appropriate lighting, can be effective interventions 7
Structured daily routines and meaningful activities tailored to the person's interests and abilities can also be beneficial 6

Antipsychotic medications should only be used when symptoms are severe, dangerous, or causing significant distress 5
Nonpharmacological interventions should be tried before considering medication, and the potential benefits of medication should outweigh the risks 4, 5
Antipsychotic medications may be considered when nonpharmacological interventions have failed 7

Low-dose atypical antipsychotics, such as risperidone, may be considered with careful risk assessment 8
The medication dose should be started at the lowest possible dose and titrated slowly to the minimum effective dose 8
Important cautions with antipsychotic use include discussing risks and benefits with the patient and surrogate decision-makers, monitoring closely for adverse effects, and being aware of increased risk of serious adverse events and potential increased mortality risk 9, 7

Regularly assessing response to treatment using quantitative measures is essential 2
If no clinically significant response occurs after a 4-week trial of an adequate antipsychotic dose, the medication should be tapered and withdrawn 9
Periodically reassessing the need for continued medication is necessary for patients who respond positively 10
If significant side effects develop, the risk/benefit balance should be reviewed, and consideration should be given to tapering or discontinuing the medication 10

The American Psychiatric Association notes that in clinical trials, the benefits of antipsychotic medications are at best small, with modest effect sizes 11
Atypical antipsychotics probably reduce agitation slightly (SMD -0.21, 95% CI -0.30 to -0.12) based on moderate-certainty evidence, although the specific citation is not provided, this fact is related to the use of atypical antipsychotics in dementia patients 11